<DOC>
	<DOCNO>NCT01154348</DOCNO>
	<brief_summary>The purpose study determine safety pharmacokinetics double-blind S-707106 alone combination open-label metformin patient type 2 diabetes mellitus</brief_summary>
	<brief_title>Study Assess Safety Pharmacokinetics Double-Blind S-707106 Alone Combination With Open-Label Metformin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Safety evaluate monitor treatment-emergent adverse event , clinical laboratory evaluation , vital sign , 12-lead electrocardiogram , 24-hour telemetry monitoring , physical exam . Specific study withdrawal criterion washout period metformin establish loss glycemic control , i.e. , glucose monitoring . Pharmacokinetic assessment monotherapy cohort versus add-on therapy perform</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Body mass index range ( 25.038 kg/m2 ) type 2 diabetes mellitus receive stable dose metformin BID previous 60 day glucose control Patients sterile agree use approve method contraception No clinically significant abnormal test Hemoglobin A1c level â‰¤10.5 % History clinical manifestation significant metabolic , hepatic , renal , hematological pulmonary , cardiovascular , gastrointestinal , urological , neurological , psychiatric disorder type 2 diabetes mellitus Uncontrolled diabetes Exclusionary labs fast blood sugar , low hemoglobin , elevate liver function test , positive result human immunodeficiency virus , hepatitis B surface antigen , antihepatitis C virus Low creatinine clearance History myocardial infarction within past 90 day cardiovascular condition Prior exposure S707106 Treatment investigational study drug within 30 day study admission day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Metformin</keyword>
</DOC>